A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kalle, Martina ^a   Papareddy, Praveen ^a   Kasetty, Gopinath ^a   Van Der Plas, Mariena J A ^a   Mörgelin, Matthias ^a   Malmsten, Martin ^b   Schmidtchen, Artur ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; GAMMA INTERFERON; HEPARIN COFACTOR II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; KYE28 PEPTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; ESCHERICHIA COLI; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; AMINO ACID SEQUENCE; ANIMAL; BACTERIA; C57BL MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MOLECULAR GENETICS; PSEUDOMONAS INFECTIONS; SHOCK, SEPTIC;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; CANDIDA ALBICANS; CELL LINE; ENDOTOXINS; HEPARIN COFACTOR II; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SHOCK, SEPTIC;

EID: 84904568109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102577     Document Type: Article

References (54)

1. French GL (2010) The continuing crisis in antibiotic resistance. Int J Antimicrob Agents 36 Suppl 3: S3-7.
2. Rossolini GM, Mantengoli E (2008) Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 14 Suppl 6: 2-8. (Pubitemid 352749376)
3. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369: 840-851.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, et al. (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329.
5. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344-353. (Pubitemid 43145611)
6. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554. (Pubitemid 36437931)
7. Kalle M, Papareddy P, Kasetty G, Tollefsen DM, Malmsten M, et al. (2013) Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol 190: 6303-6310.
8. Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38: S26-34.
9. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, et al. (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34: 285-292. (Pubitemid 43145602)
10. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238-247. (Pubitemid 37430063)
11. Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, et al. (2009) A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 13: R36.
12. Van Den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJ, et al. (2011) Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 9: 122-132.
13. Marti-Carvajal AJ, Sola I, Lathyris D, Cardona AF (2012) Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 3: CD004388.
14. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29: 2081-2089. (Pubitemid 33063534)
15. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557. (Pubitemid 44967479)
16. Fox JL (2013) Antimicrobial peptides stage a comeback. Nat Biotechnol 31: 379-382.
17. Pasupuleti M, Schmidtchen A, Malmsten M (2012) Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 32: 143-171.
18. Lai Y, Gallo RL (2009) AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 30: 131-141.
19. Harder J, Glaser R, Schroder JM (2007) Human antimicrobial proteins effectors of innate immunity. J Endotoxin Res 13: 317-338.
20. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
21. Tossi A, Sandri L, Giangaspero A (2000) Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55: 4-30.
22. Bowdish DM, Davidson DJ, Hancock RE (2006) Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol 306: 27-66. (Pubitemid 47400317)
23. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, et al. (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184: 2539-2550.
24. Kalle M, Papareddy P, Kasetty G, Morgelin M, van der Plas MJ, et al. (2012) Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis. PLoS One 7: e51313.
25. Papareddy P, Kalle M, Singh S, Morgelin M, Schmidtchen A, et al. (2014) An antimicrobial helix A-derived peptide of heparin cofactor II blocks endotoxin responses in vivo. Biochim Biophys Acta 1838: 1225-1234.
26. Singh S, Papareddy P, Kalle M, Schmidtchen A, Malmsten M (2013) Importance of lipopolysaccharide aggregate disruption for the anti-endotoxic effects of heparin cofactor II peptides. Biochim Biophys Acta 1828: 2709-2719.
27. Vandamme D, Landuyt B, Luyten W, Schoofs L (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280: 22-35.
28. Papareddy P, Rydengard V, Pasupuleti M, Walse B, Morgelin M, et al. (2010) Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 6: e1000857.
29. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455-2464. (Pubitemid 43201696)
30. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P (1991) Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 137: 167-173.
31. Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, et al. (2010) C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 285: 28387-28398.
32. Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175. (Pubitemid 351266501)
33. Sonesson A, Kasetty G, Olin AI, Malmsten M, Morgelin M, et al. (2011) Thymic stromal lymphopoietin exerts antimicrobial activities. Exp Dermatol 20: 1004-1010.
34. Kasetty G, Papareddy P, Kalle M, Rydengard V, Walse B, et al. (2011) The C-terminal sequence of several human serine proteases encodes host defense functions. J Innate Immun 3: 471-482.
35. Pasupuleti M, Walse B, Svensson B, Malmsten M, Schmidtchen A (2008) Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach. Biochemistry 47: 9057-9070.
36. Fritsche TR, Rhomberg PR, Sader HS, Jones RN (2008) Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother 61: 1092-1098. (Pubitemid 351524455)
37. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16: 3-9. (Pubitemid 38147427)
38. Jerala R (2007) Structural biology of the LPS recognition. Int J Med Microbiol 297: 353-363.
39. Kasetty G, Papareddy P, Kalle M, Rydengard V, Morgelin M, et al. (2011) Structure-activity studies and therapeutic potential of host defense peptides of human thrombin. Antimicrob Agents Chemother 55: 2880-2890.
40. Lehrer RI, Lichtenstein AK, Ganz T (1993) Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11: 105-128. (Pubitemid 23115003)
41. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39: 165-228.
42. Levi M, Ten CateH(1999) Disseminated intravascular coagulation. N Engl J Med 341: 586-592. (Pubitemid 29384168)
43. Levi M, de Jonge E, van der Poll T, ten Cate H (1999) Disseminated intravascular coagulation. Thromb Haemost 82: 695-705.
44. Schuerholz T, Brandenburg K, Marx G (2012) Antimicrobial peptides and their potential application in inflammation and sepsis. Crit Care 16: 207.
45. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, et al. (2005) Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459. (Pubitemid 40489520)
46. Herwald H, Morgelin M, Olsen A, Rhen M, Dahlback B, et al. (1998) Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat Med 4: 298-302. (Pubitemid 28144087)
47. Oehmcke S, Herwald H (2010) Contact system activation in severe infectious diseases. J Mol Med (Berl) 88: 121-126.
48. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, et al. (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33: 341-348. (Pubitemid 40216547)
49. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, et al. (2007) Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 571: 231-239. (Pubitemid 47379694)
50. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, et al. (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11: R49.
51. de Jong HK, van der Poll T, Wiersinga WJ (2010) The systemic proinflammatory response in sepsis. J Innate Immun 2: 422-430.
52. Faix JD (2013) Biomarkers of sepsis. Crit Rev Clin Lab Sci 50: 23-36.
53. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR (1994) Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 81: 1306-1308. (Pubitemid 24275149)
54. Albiger B, Dahlberg S, Henriques-Normark B, Normark S (2007) Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J Intern Med 261: 511-528. (Pubitemid 46835986)